|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 237/34 | (2006.01) |
| C07D 471/04 | (2006.01) |
| (11) | Number of the document | 4363406 |
| (13) | Kind of document | T |
| (96) | European patent application number | 22744149.0 |
| Date of filing the European patent application | 2022-07-01 | |
| (97) | Date of publication of the European application | 2024-05-08 |
| (45) | Date of publication and mention of the grant of the patent | 2025-09-10 |
| (46) | Date of publication of the claims translation | 2025-12-29 |
| (86) | Number | PCT/EP2022/068292 |
| Date | 2022-07-01 |
| (87) | Number | WO 2023/275366 |
| Date | 2023-01-05 |
| (30) | Number | Date | Country code |
| 202163217970 P | 2021-07-02 | US |
| (72) |
JOHANSSON, Lars Anders Mikael , SE
GRADÉN, Henrik , SE
BERGONZINI, Giulia , SE
SUGAMA, Hiroshi , JP
MATSUMURA, Takehiko , JP
|
| (73) |
Astrazeneca AB ,
151 85 Södertälje,
SE
Mitsubishi Tanabe Pharma Corporation , 3-2-10, Dosho-machi, Chuo-ku,, Osaka-shi, Osaka 541-8505, JP |
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | NLRP3 inflamasomų inhibitoriai |
| NLRP3 INFLAMMASOME INHIBITORS |